Related Experiment Video

Updated: May 12, 2026

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
09:49

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

Published on: July 5, 2019

RNA-based precision medicine in glioblastoma driven by oncogenic gene fusions

Maël Bouillon1, Clémentine Lapoujade1, Laëtitia Basset1,2

  • 1Université D'Angers, INSERM, CNRS, CRCINA, 49000 Angers, France.

Molecular Therapy. Oncology
|May 11, 2026
PubMed

Insights

RNA interference offers a promising new therapy for glioblastoma, a deadly brain cancer. This approach targets gene fusions driving tumor growth, potentially improving patient survival with fewer side effects than current treatments.

Area of Science:

  • Neuro-oncology
  • Molecular Biology
  • Genetics

Background:

  • Glioblastoma is the most common and lethal primary brain tumor.
  • Gene fusions resulting from chromosomal rearrangements drive glioblastoma tumorigenesis by activating tyrosine kinase receptors.
  • Current treatments like tyrosine kinase inhibitors show limited clinical efficacy in glioblastoma.

Purpose of the Study:

  • To review advances in RNA interference (RNAi) technology for targeting oncogenic gene fusions in glioblastoma.
  • To discuss the potential of RNAi-based therapies to overcome the limitations of current treatments.
  • To highlight the improved stability, specificity, and delivery of RNAi agents.

Main Methods:

  • Review of recent biotechnological advancements in RNA interference (RNAi).
  • Discussion of small interfering RNAs (siRNAs), micro-RNAs (miRNAs), antisense oligonucleotides, and aptamers.
  • Analysis of improved delivery systems for crossing the blood-brain barrier.

Main Results:

  • RNA interference offers a targeted approach to silence oncogenic gene fusions, sparing healthy cells.
  • Advances in biotechnology have enhanced the stability, specificity, and delivery of RNAi agents.
  • Improved delivery systems show potential for effective blood-brain barrier penetration.

Conclusions:

  • RNA interference-based therapy is a promising strategy for glioblastoma treatment.
  • Targeting oncogenic gene fusions with RNAi could lead to improved patient survival.
  • Further research in RNAi holds potential for innovative therapeutic applications in neuro-oncology.
Keywords:
RNA interferencegene fusionglioblastomaprecision medicinetargeted therapy

More Related Videos

Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma10:58

Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma

Published on: February 22, 2015

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...